Boise and Meridian, Idaho About Glossary Questions Questions about an appointment? (208) 706-4650
Shelley K. Perkins, MD Breast Surgery

Home › Diagnosis and treatment › Hormone receptor positive

Diagnosis & treatment

Hormone receptor positive, HER2 negative breast cancer

Most breast cancers are this type. The cells carry estrogen receptors, progesterone receptors, or both, which means estrogen in the body helps them grow. That is a weakness that can be used, and for this type the daily pill is the long-term treatment and surgery is the short-term one.

What hormone receptor positive breast cancer is

Most breast cancers are this type. The cells carry , , or both, which means estrogen in the body helps them grow. That is a weakness that can be used: medicines that block estrogen or lower it starve the cancer, and they work for years after surgery to keep it from coming back. A report is called ER positive when at least 1 in 100 cancer cells stains for the receptor; between 1 and 10 it may be called ER low positive, which is treated a little differently.

What usually happens next with hormone receptor positive breast cancer, in order

  1. Surgery first, usually. A or a , with a to check the first few lymph nodes. For larger cancers where a lumpectomy would be difficult, several months of an anti-estrogen pill before surgery can shrink the cancer enough to allow one.
  2. The final report. The actual size, the , and the nodes set the final . For invasive cancer, a margin is clear when there is no cancer at the inked edge of the tissue.
  3. A test to decide about chemotherapy. For many people with this type, especially when the nodes are clear, a test such as is run on the tumor. It looks at the activity of 21 genes and gives a score that predicts whether chemotherapy would add anything to the anti-estrogen pill. For a large share of people the answer is that it would not, and they never have chemotherapy.
  4. Radiation, after a lumpectomy, and after a mastectomy when the cancer was large or several nodes were involved.
  5. Endocrine therapy. A daily pill for five years, often extended to seven to ten. Before menopause it is usually , sometimes with medicine that switches the ovaries off. After menopause it is usually an . For higher-risk cancers, a newer pill called a may be added for the first two to three years.

Choices you will be asked about with hormone receptor positive breast cancer

Lumpectomy or mastectomy. Whether to have chemotherapy if the score is in the middle range. Which endocrine pill, which depends partly on side effects. Whether to add ovarian suppression before menopause, which is a trade between a lower chance of recurrence and menopause symptoms arriving early. If a mastectomy, reconstruction and its timing.

In plain terms

For this type, the pill is the long-term treatment and surgery is the short-term one. Chemotherapy is the exception rather than the rule, and a test on your own tumor usually settles it.

Questions to bring to your appointment

These are built for hormone receptor positive breast cancer. The report decoder narrows the list further from your own report, and the print button there puts it on paper with room to write. Bring someone with you if you can; two sets of ears hear more than one.

Where this comes from

Sources, checked 9 September 2026

This page is written in plain language from the current NCCN Guidelines for Patients: Invasive Breast Cancer (2026 edition, based on NCCN Guidelines for Breast Cancer version 2.2026), which Dr. Perkins shared as the reference for this page and which is free to read at NCCN.org/patientguidelines, along with NCCN's separate patient guides for DCIS and for metastatic breast cancer. NCCN's material is copyrighted and nothing here reproduces it; readers who want the full detail should go to the source. Breastcancer.org publishes a free guide to reading a pathology report, updated June 2026, at breastcancer.org/pathology-report. Margin definitions follow the Society of Surgical Oncology and American Society for Radiation Oncology consensus statements for invasive cancer (2014) and DCIS (2016). Receptor cutoffs follow the American Society of Clinical Oncology and College of American Pathologists guidelines. Staging follows the American Joint Committee on Cancer, eighth edition. Every clinical statement on this page is listed on the site's verification ledger, and Dr. Perkins read the site on 13 September 2026.

This page is education. It does not diagnose, and the summary it builds is not a treatment plan. Your plan is made with your own care team from your own results.

Published 7 September 2026 as part of the guide; a page of its own since 9 September 2026.

Call the office